...
首页> 外文期刊>Trials >Development of a Core Outcome Set and Minimum Reporting Set for intervention studies in growth restriction in the NEwbOrN (COSNEON): study protocol for a Delphi study
【24h】

Development of a Core Outcome Set and Minimum Reporting Set for intervention studies in growth restriction in the NEwbOrN (COSNEON): study protocol for a Delphi study

机译:开发新的核心结果集和最小报告集,用于NEwbOrN(COSNEON)中生长受限干预研究:Delphi研究的研究方案

获取原文
           

摘要

Growth restriction in the newborn (GRN) can predispose to severe complications including hypoglycemia, sepsis, and necrotizing enterocolitis. Different interventions and treatments, such as feeding strategies, for GRN have specific benefits and risks. Comparing results from studies investigating intervention studies in GRN is challenging due to the use of different baseline and study characteristics and differences in reported study outcomes. In order to be able to compare study results and to allow pooling of data, uniform reporting of study characteristics (minimum reporting set [MRS]) and outcomes (core outcome set [COS]) are needed. We aim to develop both an MRS and a COS for interventional and treatment studies in GRN. The MRS and COS will be developed according to Delphi methodology. First, a scoping literature search will be performed to identify study characteristics and outcomes in research focused on interventions/treatments in the GRN. An international group of stakeholders, including experts (clinicians working with GRN, and researchers who focus on GRN) and lay experts ([future] parents of babies with GRN), will be questioned to rate the importance of the study characteristics and outcomes in three rounds. After three rounds there will be two consensus meetings: a face-to-face meeting and an electronic meeting. During the consensus meetings multiple representatives of stakeholder groups will reach agreement upon which study characteristics and outcomes will be included into the COS and MRS. The second electronic consensus meeting will be used to test if an electronic meeting is as effective as a face-to-face meeting. In our opinion a COS alone is not sufficient to compare and aggregate trial data. Hence, to ensure optimum comparison we also will develop an MRS. Interventions in GRN infants are often complicated by coexisting preterm birth. A COS already has been developed for preterm birth. The majority of GRN infants are born at term, however, and we therefore chose to develop a separate COS for interventions in GRN, which can be combined (with expected overlap) in intervention studies enrolling preterm GRN babies. Not applicable. This study is registered in the Core Outcome Measures for Effectiveness ( COMET ) database. Registered on 30 June 2017.
机译:新生儿(GRN)的生长受限会导致严重的并发症,包括低血糖,败血症和坏死性小肠结肠炎。 GRN的不同干预措施和治疗方法(例如喂养策略)具有特定的收益和风险。由于使用了不同的基线和研究特征以及所报告的研究结果的差异,因此比较研究GRN干预研究的研究结果具有挑战性。为了能够比较研究结果并允许汇总数据,需要对研究特征(最小报告集[MRS])和结果(核心结果集[COS])进行统一报告。我们旨在为GRN的介入和治疗研究开发MRS和COS。 MRS和COS将根据Delphi方法进行开发。首先,将进行范围广泛的文献检索,以识别针对GRN干预措施的研究特征和结果。一个国际利益相关者小组,包括专家(与GRN合作的临床医生以及专注于GRN的研究人员)和非专业专家(与GRN婴儿有关的未来父母)将受到质疑,以对三个方面的研究特征和结果的重要性进行评估回合。经过三轮之后,将举行两次共识会议:面对面会议和电子会议。在共识会议期间,利益相关方团体的多位代表将达成共识,将研究特征和结果纳入COS和MRS。第二次电子共识会议将用于测试电子会议是否与面对面会议一样有效。我们认为,仅靠COS不足以比较和汇总试验数据。因此,为了确保最佳比较,我们还将开发MRS。共存早产常常使对GRN婴儿的干预变得复杂。已经为早产开发了COS。但是,大多数GRN婴儿是足月出生的,因此,我们选择开发单独的COS进行GRN干预,可以将其与参与早产GRN婴儿的干预研究相结合(预期有重叠)。不适用。这项研究已注册在“核心成果有效措施”(COMET)数据库中。 2017年6月30日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号